Bote-de Cabo H, Siringo M, Conde E, Hernández S, López-Ríos F, Castelo-Loureiro A, García-Lorenzo E, Baena J, Herrera M, Enguita AB, Ruano Y, Zugazagoitia J, Paz-Ares L (2025).
Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC.
Jiménez-Reinoso, A, Molero-Abraham, M, Cirauqui, C, Blanco, B, Garrido-Martin, EM, Nehme-Alvarez, D, Domínguez-Alonso, C, Ramírez-Fernández, A, Díez-Alonso, L, Nuñez-Buiza, A, González-Murillo, A, Tobes, R, Pareja, E, Ramírez-Orellana, M, Rodriguez-Peralto, JL, Ferrer, I, Zugazagoitia, J, Paz-Ares, L, Alvarez-Vallina, L (2024).
CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
Santoro, A, Pilar, G, Tan, DSW, Zugazagoitia, J, Shepherd, FA, Bearz, A, Barlesi, F, Kim, TM, Overbeck, TR, Felip, E, Cai, C, Simantini, E, Mcculloch, T, Schaefer, ES (2024).
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Molero, A, Hernandez, S, Alonso, M, Peressini, M, Curto, D, Lopez-Rios, F, Conde, E (2024).
Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms
Nassar, AH, Kim, SY, Aredo, J, Feng, JM, Shepherd, F, Xu, C, Kaldas, D, Gray, JE, Dilling, TJ, Neal, JW, Wakelee, HA, Liu, YF, Lin, SH, Abuali, T, Amini, A, Nie, YA, Patil, T, Lobachov, A, Bar, J, Fitzgerald, B, Fujiwara, Y, Marron, TU, Thummalapalli, R, Yu, HLA, Owen, DH, Sharp, J, Farid, S, Rocha, P, Arriola, E, 'Aiello, A, Cheng, HY, Whitaker, R, Parikh, K, Ashara, Y, Chen, LX, Sankar, K, Harris, JP, Nagasaka, M, Ayanambakkam, A, Velazquez, AI, Ragavan, M, Lin, JJ, Piotrowska, ZF, Wilgucki, M, Reuss, J, Luders, H, Grohe, C, Espinar, JB, Feiner, E, Punekar, SR, Gupta, S, Leal, T, Kwiatkowski, DJ, Mak, RH, Adib, E, Naqash, AR, Goldberg, SB (2024).
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Ponce, S, Cedrés, S, Ricordel, C, Isambert, N, Viteri, S, Herrera-Juarez, M, Martinez-Marti, A, Navarro, A, Lederlin, M, Serres, X, Zugazagoitia, J, Vetrhus, S, Jaderberg, M, Hansen, TB, Levitsky, V, Paz-Ares, L (2023).
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
Isla, D, Sánchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabé, R (2023).
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement